Review Article | Published:

Environmental, genetic and epigenetic contributions to cocaine addiction

Neuropsychopharmacologyvolume 43pages14711480 (2018) | Download Citation


Decades of research on cocaine has produced volumes of data that have answered many important questions about the nature of this highly addictive drug. Sadly, none of this information has translated into the development of effective therapies for the treatment of cocaine addiction. This review endeavors to assess the current state of cocaine research in an attempt to identify novel pathways for therapeutic development. For example, risk of cocaine addiction is highly heritable but genome-wide analyses comparing cocaine-dependent individuals to controls have not resulted in promising targets for drug development. Is this because the genetics of addiction is too complex or because the existing research methodologies are inadequate? Likewise, animal studies have revealed dozens of enduring changes in gene expression following prolonged exposure to cocaine, none of which have translated into therapeutics either because the resulting compounds were ineffective or produced intolerable side-effects. Recently, attention has focused on epigenetic modifications resulting from repeated cocaine intake, some of which appear to be heritable through changes in the germline. While epigenetic changes represent new vistas for therapeutic development, selective manipulation of epigenetic marks is currently challenging even in animals such that translational potential is a distant prospect. This review will reveal that despite the enormous progress made in understanding the molecular and physiological bases of cocaine addiction, there is much that remains a mystery. Continued advances in genetics and molecular biology hold potential for revealing multiple pathways toward the development of treatments for the continuing scourge of cocaine addiction.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Ahrnsbrak R, Bose J, Hedden S, Lipari R, Park-Lee E. Key substance use and mental health indicators in the United States: Results from the 2016 National Survey on Drug Use and Health. Administration SAaMHS. 2017.

  2. 2.

    Pierce RC, O’Brien CP, Kenny PJ, Vanderschuren LJ. Rational development of addiction pharmacotherapies: successes, failures, and prospects. Cold Spring Harb Perspect Med. 2012;2:a012880.

  3. 3.

    Kampman KM, Leiderman D, Holmes T, LoCastro J, Bloch DA, Reid MS, et al. Cocaine rapid efficacy screening trials (CREST): lessons learned. Addiction. 2005;100:102–10.

  4. 4.

    Nuijten M, Blanken P, van de Wetering B, Nuijen B, van den Brink W, Hendriks VM. Sustained-release dexamfetamine in the treatment of chronic cocaine-dependent patients on heroin-assisted treatment: a randomised, double-blind, placebo-controlled trial. Lancet. 2016;387:2226–34.

  5. 5.

    Shearer J, Wodak A, van Beek I, Mattick RP, Lewis J. Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction. 2003;98:1137–41.

  6. 6.

    Dursteler-MacFarland KM, Farronato NS, Strasser J, Boss J, Kuntze MF, Petitjean SA, et al. A randomized, controlled, pilot trial of methylphenidate and cognitive-behavioral group therapy for cocaine dependence in heroin prescription. J Clin Psychopharmacol. 2013;33:104–8.

  7. 7.

    Grabowski J, Rhoades H, Schmitz J, Stotts A, Daruzska LA, Creson D, et al. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J Clin Psychopharmacol. 2001;21:522–6.

  8. 8.

    Tsuang MT, Lyons MJ, Meyer JM, Doyle T, Eisen SA, Goldberg J, et al. Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities. Arch Gen Psychiatry. 1998;55:967–72.

  9. 9.

    Kendler KS, Jacobson KC, Prescott CA, Neale MC. Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. Am J Psychiatry. 2003;160:687–95.

  10. 10.

    Olivares EL, Kendler KS, Neale MC, Gillespie NA. The genetic and environmental association between parental monitoring and risk of cannabis, stimulants, and cocaine initiation in a sample of male twins: does parenting matter? Twin Res Hum Genet. 2016;19:297–305.

  11. 11.

    Wurbel H. Ideal homes? Housing effects on rodent brain and behaviour. Trends Neurosci. 2001;24:207–11.

  12. 12.

    Hill SY, Powell BJ. Cocaine and morphine self-administration: effects of differential rearing. Pharmacol Biochem Behav. 1976;5:701–4.

  13. 13.

    Bowling SL, Bardo MT. Locomotor and rewarding effects of amphetamine in enriched, social, and isolate reared rats. Pharmacol Biochem Behav. 1994;48:459–64.

  14. 14.

    Green TA, Gehrke BJ, Bardo MT. Environmental enrichment decreases intravenous amphetamine self-administration in rats: dose-response functions for fixed- and progressive-ratio schedules. Psychopharmacology. 2002;162:373–8.

  15. 15.

    Bardo MT, Klebaur JE, Valone JM, Deaton C. Environmental enrichment decreases intravenous self-administration of amphetamine in female and male rats. Psychopharmacology. 2001;155:278–84.

  16. 16.

    Fowler SC, Johnson JS, Kallman MJ, Liou JR, Wilson MC, Hikal AH. In a drug discrimination procedure isolation-reared rats generalize to lower doses of cocaine and amphetamine than rats reared in an enriched environment. Psychopharmacology. 1993;110:115–8.

  17. 17.

    Solinas M, Thiriet N, El Rawas R, Lardeux V, Jaber M. Environmental enrichment during early stages of life reduces the behavioral, neurochemical, and molecular effects of cocaine. Neuropsychopharmacology. 2009;34:1102–11.

  18. 18.

    Chauvet C, Lardeux V, Goldberg SR, Jaber M, Solinas M. Environmental enrichment reduces cocaine seeking and reinstatement induced by cues and stress but not by cocaine. Neuropsychopharmacology. 2009;34:2767–78.

  19. 19.

    Moos RH. Theory-based active ingredients of effective treatments for substance use disorders. Drug Alcohol Depend. 2007;88:109–21.

  20. 20.

    Merikangas KR, Stolar M, Stevens DE, Goulet J, Preisig MA, Fenton B, et al. Familial transmission of substance use disorders. Arch Gen Psychiatry. 1998;55:973–9.

  21. 21.

    Bierut LJ, Dinwiddie SH, Begleiter H, Crowe RR, Hesselbrock V, Nurnberger JI Jr., et al. Familial transmission of substance dependence: alcohol, marijuana, cocaine, and habitual smoking: a report from the Collaborative Study on the Genetics of Alcoholism. Arch Gen Psychiatry. 1998;55:982–8.

  22. 22.

    Kendler KS, Ohlsson H, Maes HH, Sundquist K, Lichtenstein P, Sundquist J. A population-based Swedish twin and sibling study of cannabis, stimulant and sedative abuse in men. Drug Alcohol Depend. 2015;149:49–54.

  23. 23.

    Kendler KS, Myers J, Prescott CA. Specificity of genetic and environmental risk factors for symptoms of cannabis, cocaine, alcohol, caffeine, and nicotine dependence. Arch Gen Psychiatry. 2007;64:1313–20.

  24. 24.

    Kendler KS, Karkowski LM, Neale MC, Prescott CA. Illicit psychoactive substance use, heavy use, abuse, and dependence in a US population-based sample of male twins. Arch Gen Psychiatry. 2000;57:261–9.

  25. 25.

    Kendler KS, Prescott CA. Cocaine use, abuse and dependence in a population-based sample of female twins. Br J Psychiatry. 1998;173:345–50.

  26. 26.

    van den Bree MB, Johnson EO, Neale MC, Pickens RW. Genetic and environmental influences on drug use and abuse/dependence in male and female twins. Drug Alcohol Depend. 1998;52:231–41.

  27. 27.

    Goldman D, Oroszi G, Ducci F. The genetics of addictions: uncovering the genes. Nat Rev Genet. 2005;6:521–32.

  28. 28.

    Merikangas KR, Avenevoli S. Implications of genetic epidemiology for the prevention of substance use disorders. Addict Behav. 2000;25:807–20.

  29. 29.

    Agrawal A, Verweij KJ, Gillespie NA, Heath AC, Lessov-Schlaggar CN, Martin NG, et al. The genetics of addiction-a translational perspective. Transl Psychiatry. 2012;2:e140.

  30. 30.

    Kalayasiri R, Sughondhabirom A, Gueorguieva R, Coric V, Lynch WJ, Lappalainen J, et al. Dopamine beta-hydroxylase gene (DbetaH) -1021C-- > T influences self-reported paranoia during cocaine self-administration. Biol Psychiatry. 2007;61:1310–3.

  31. 31.

    Luo X, Kranzler H, Lappalainen J, Rosenheck R, Charney D, Zuo L, et al. CALCYON gene variation, schizophrenia, and cocaine dependence. Am J Med Genet Part B Neuropsychiatr Genet. 2004;125B:25–30.

  32. 32.

    Ittiwut R, Listman JB, Ittiwut C, Cubells JF, Weiss RD, Brady K, et al. Association between polymorphisms in catechol-O-methyltransferase (COMT) and cocaine-induced paranoia in European-American and African-American populations. Am J Med Genet Part B Neuropsychiatr Genet. 2011;156B:651–60.

  33. 33.

    Lohoff FW, Weller AE, Bloch PJ, Nall AH, Ferraro TN, Kampman KM, et al. Association between the catechol-O-methyltransferase Val158Met polymorphism and cocaine dependence. Neuropsychopharmacology. 2008;33:3078–84.

  34. 34.

    Multani PK, Clarke TK, Narasimhan S, Ambrose-Lanci L, Kampman KM, Pettinati HM, et al. Neuronal calcium sensor-1 and cocaine addiction: a genetic association study in African-Americans and European Americans. Neurosci Lett. 2012;531:46–51.

  35. 35.

    Martínez-Rivera A, Hao J, Tropea TF, Giordano TP, Kosovsky M, Rice RC, Lee A, Huganir RL, Striessnig J, Addy NA, Han S, Rajadhyaksha AM. Enhancing Ca1.3 L-type Ca2+ channel activity promotes cocaine and mood-related behaviors via overlapping AMPA receptor mechanisms in the nucleus accumbens. Mol Psychiatry. 2017;22:1735–45.

  36. 36.

    Zuo L, Kranzler HR, Luo X, Yang BZ, Weiss R, Brady K, et al. Interaction between two independent CNR1 variants increases risk for cocaine dependence in European Americans: a replication study in family-based sample and population-based sample. Neuropsychopharmacology. 2009;34:1504–13.

  37. 37.

    Clarke TK, Bloch PJ, Ambrose-Lanci LM, Ferraro TN, Berrettini WH, Kampman KM, et al. Further evidence for association of polymorphisms in the CNR1 gene with cocaine addiction: confirmation in an independent sample and meta-analysis. Addict Biol. 2013;18:702–8.

  38. 38.

    Crist RC, Ambrose-Lanci LM, Vaswani M, Clarke TK, Zeng A, Yuan C, et al. Case–control association analysis of polymorphisms in the delta-opioid receptor, OPRD1, with cocaine and opioid addicted populations. Drug Alcohol Depend. 2013;127:122–8.

  39. 39.

    Crist RC, Doyle GA, Kampman KM, Berrettini WH. A delta-opioid receptor genetic variant is associated with abstinence prior to and during cocaine dependence treatment. Drug Alcohol Depend. 2016;166:268–71.

  40. 40.

    Dahl JP, Cubells JF, Ray R, Weller AE, Lohoff FW, Ferraro TN, et al. Analysis of variations in the tryptophan hydroxylase-2 (TPH2) gene in cocaine dependence. Addict Biol. 2006;11:76–83.

  41. 41.

    Dahl JP, Kampman KM, Oslin DW, Weller AE, Lohoff FW, Ferraro TN, et al. Association of a polymorphism in the Homer1 gene with cocaine dependence in an African American population. Psychiatr Genet. 2005;15:277–83.

  42. 42.

    Kuryatov A, Berrettini W, Lindstrom J. Acetylcholine receptor (AChR) alpha5 subunit variant associated with risk for nicotine dependence and lung cancer reduces (alpha4beta2)(2)alpha5 AChR function. Mol Pharmacol. 2011;79:119–25.

  43. 43.

    Berrettini W, Yuan X, Tozzi F, Song K, Francks C, Chilcoat H, et al. Alpha-5/alpha-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol Psychiatry. 2008;13:368–73.

  44. 44.

    Saccone SF, Hinrichs AL, Saccone NL, Chase GA, Konvicka K, Madden PA, et al. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet. 2007;16:36–49.

  45. 45.

    Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature. 2008;452:638–42.

  46. 46.

    Bierut LJ, Stitzel JA, Wang JC, Hinrichs AL, Grucza RA, Xuei X, et al. Variants in nicotinic receptors and risk for nicotine dependence. Am J Psychiatry. 2008;165:1163–71.

  47. 47.

    Demers CH, Bogdan R, Agrawal A. The Genetics, Neurogenetics and Pharmacogenetics of Addiction. Curr Behav Neurosci Rep. 2014;1:33–44.

  48. 48.

    Grucza RA, Wang JC, Stitzel JA, Hinrichs AL, Saccone SF, Saccone NL, et al. A risk allele for nicotine dependence in CHRNA5 is a protective allele for cocaine dependence. Biol Psychiatry. 2008;64:922–9.

  49. 49.

    Sadler B, Haller G, Agrawal A, Culverhouse R, Bucholz K, Brooks A, et al. Variants near CHRNB3-CHRNA6 are associated with DSM-5 cocaine use disorder: evidence for pleiotropy. Sci Rep. 2014;4:4497.

  50. 50.

    Sherva R, Kranzler HR, Yu Y, Logue MW, Poling J, Arias AJ, et al. Variation in nicotinic acetylcholine receptor genes is associated with multiple substance dependence phenotypes. Neuropsychopharmacology. 2010;35:1921–31.

  51. 51.

    Hansen ST, Mark GP. The nicotinic acetylcholine receptor antagonist mecamylamine prevents escalation of cocaine self-administration in rats with extended daily access. Psychopharmacology. 2007;194:53–61.

  52. 52.

    Levin ED, Mead T, Rezvani AH, Rose JE, Gallivan C, Gross R. The nicotinic antagonist mecamylamine preferentially inhibits cocaine vs. food self-administration in rats. Physiol Behav. 2000;71:565–70.

  53. 53.

    Fowler CD, Lu Q, Johnson PM, Marks MJ, Kenny PJ. Habenular alpha5 nicotinic receptor subunit signalling controls nicotine intake. Nature. 2011;471:597–601.

  54. 54.

    Jensen KP. A review of genome-wide association studies of stimulant and opioid use disorders. Mol Neuropsychiatry. 2016;2:37–45.

  55. 55.

    Gelernter J, Sherva R, Koesterer R, Almasy L, Zhao H, Kranzler HR, et al. Genome-wide association study of cocaine dependence and related traits: FAM53B identified as a risk gene. Mol Psychiatry. 2014;19:717–23.

  56. 56.

    Thermes V, Candal E, Alunni A, Serin G, Bourrat F, Joly JS. Medaka simplet (FAM53B) belongs to a family of novel vertebrate genes controlling cell proliferation. Development. 2006;133:1881–90.

  57. 57.

    Aoki M, Segawa H, Naito M, Okamoto H. Identification of possible downstream genes required for the extension of peripheral axons in primary sensory neurons. Biochem Biophys Res Commun. 2014;445:357–62.

  58. 58.

    Dickson PE, Miller MM, Calton MA, Bubier JA, Cook MN, Goldowitz D, et al. Systems genetics of intravenous cocaine self-administration in the BXD recombinant inbred mouse panel. Psychopharmacology. 2016;233:701–14.

  59. 59.

    Hao K, Chudin E, McElwee J, Schadt EE. Accuracy of genome-wide imputation of untyped markers and impacts on statistical power for association studies. BMC Genet. 2009;10:27.

  60. 60.

    Cervantes MC, Laughlin RE, Jentsch JD. Cocaine self-administration behavior in inbred mouse lines segregating different capacities for inhibitory control. Psychopharmacology. 2013;229:515–25.

  61. 61.

    Hu Y, Salmeron BJ, Gu H, Stein EA, Yang Y. Impaired functional connectivity within and between frontostriatal circuits and its association with compulsive drug use and trait impulsivity in cocaine addiction. JAMA Psychiatry. 2015;72:584–92.

  62. 62.

    Groman SM, Lee B, Seu E, James AS, Feiler K, Mandelkern MA, et al. Dysregulation of D(2)-mediated dopamine transmission in monkeys after chronic escalating methamphetamine exposure. J Neurosci. 2012;32:5843–52.

  63. 63.

    Ashok AH, Mizuno Y, Volkow ND, Howes OD. Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine: a systematic review and meta-analysis. JAMA Psychiatry. 2017;74:511–9.

  64. 64.

    Mandt BH, Schenk S, Zahniser NR, Allen RM. Individual differences in cocaine-induced locomotor activity in male Sprague–Dawley rats and their acquisition of and motivation to self-administer cocaine. Psychopharmacology. 2008;201:195–202.

  65. 65.

    Piazza PV, Deminiere JM, Le Moal M, Simon H. Factors that predict individual vulnerability to amphetamine self-administration. Science. 1989;245:1511–3.

  66. 66.

    Wiltshire T, Ervin RB, Duan H, Bogue MA, Zamboni WC, Cook S, et al. Initial locomotor sensitivity to cocaine varies widely among inbred mouse strains. Genes Brain Behav. 2015;14:271–80.

  67. 67.

    Meyer AC, Rahman S, Charnigo RJ, Dwoskin LP, Crabbe JC, Bardo MT. Genetics of novelty seeking, amphetamine self-administration and reinstatement using inbred rats. Genes Brain Behav. 2010;9:790–8.

  68. 68.

    Ward AS, Li DH, Luedtke RR, Emmett-Oglesby MW. Variations in cocaine self-administration by inbred rat strains under a progressive-ratio schedule. Psychopharmacology. 1996;127:204–12.

  69. 69.

    Freeman KB, Kearns DN, Kohut SJ, Riley AL. Strain differences in patterns of drug-intake during prolonged access to cocaine self-administration. Behav Neurosci. 2009;123:156–64.

  70. 70.

    Jastrzebska J, Frankowska M, Szumiec L, Sadakierska-Chudy A, Haduch A, Smaga I, et al. Cocaine self-administration in Wistar-Kyoto rats: a behavioral and biochemical analysis. Behav Brain Res. 2015;293:62–73.

  71. 71.

    Kosten TA, Zhang XY, Haile CN. Strain differences in maintenance of cocaine self-administration and their relationship to novelty activity responses. Behav Neurosci. 2007;121:380–8.

  72. 72.

    Kumar V, Kim K, Joseph C, Kourrich S, Yoo SH, Huang HC, et al. C57BL/6N mutation in cytoplasmic FMRP interacting protein 2 regulates cocaine response. Science. 2013;342:1508–12.

  73. 73.

    Vallender EJ, Goswami DB, Shinday NM, Westmoreland SV, Yao WD, Rowlett JK. Transcriptomic profiling of the ventral tegmental area and nucleus accumbens in rhesus macaques following long-term cocaine self-administration. Drug Alcohol Depend. 2017;175:9–23.

  74. 74.

    Feng J, Wilkinson M, Liu X, Purushothaman I, Ferguson D, Vialou V, et al. Chronic cocaine-regulated epigenomic changes in mouse nucleus accumbens. Genome Biol. 2014;15:R65.

  75. 75.

    Freeman WM, Nader MA, Nader SH, Robertson DJ, Gioia L, Mitchell SM, et al. Chronic cocaine-mediated changes in non-human primate nucleus accumbens gene expression. J Neurochem. 2001;77:542–9.

  76. 76.

    McClung CA, Nestler EJ. Regulation of gene expression and cocaine reward by CREB and DeltaFosB. Nat Neurosci. 2003;6:1208–15.

  77. 77.

    Nestler EJ. Molecular mechanisms of drug addiction. Neuropharmacology. 2004;47:24–32.

  78. 78.

    Robison AJ, Nestler EJ. Transcriptional and epigenetic mechanisms of addiction. Nat Rev Neurosci. 2011;12:623–37.

  79. 79.

    Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet. 2008;9:465–76.

  80. 80.

    Poulsen P, Esteller M, Vaag A, Fraga MF. The epigenetic basis of twin discordance in age-related diseases. Pediatr Res. 2007;61:38R–42R.

  81. 81.

    Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, Ballestar ML, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA. 2005;102:10604–9.

  82. 82.

    Renthal W, Kumar A, Xiao G, Wilkinson M, Covington HE 3rd, Maze I, et al. Genome-wide analysis of chromatin regulation by cocaine reveals a role for sirtuins. Neuron. 2009;62:335–48.

  83. 83.

    Malvaez M, Sanchis-Segura C, Vo D, Lattal KM, Wood MA. Modulation of chromatin modification facilitates extinction of cocaine-induced conditioned place preference. Biol Psychiatry. 2010;67:36–43.

  84. 84.

    Kumar A, Choi KH, Renthal W, Tsankova NM, Theobald DE, Truong HT, et al. Chromatin remodeling is a key mechanism underlying cocaine-induced plasticity in striatum. Neuron. 2005;48:303–14.

  85. 85.

    Wang L, Lv Z, Hu Z, Sheng J, Hui B, Sun J, et al. Chronic cocaine-induced H3 acetylation and transcriptional activation of CaMKIIalpha in the nucleus accumbens is critical for motivation for drug reinforcement. Neuropsychopharmacology. 2010;35:913–28.

  86. 86.

    Renthal W, Maze I, Krishnan V, Covington HE 3rd, Xiao G, Kumar A, et al. Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli. Neuron. 2007;56:517–29.

  87. 87.

    Taniguchi M, Carreira MB, Smith LN, Zirlin BC, Neve RL, Cowan CW. Histone deacetylase 5 limits cocaine reward through cAMP-induced nuclear import. Neuron. 2012;73:108–20.

  88. 88.

    Walker DM, Cates HM, Heller EA, Nestler EJ. Regulation of chromatin states by drugs of abuse. Curr Opin Neurobiol. 2015;30:112–21.

  89. 89.

    Maze I, Feng J, Wilkinson MB, Sun H, Shen L, Nestler EJ. Cocaine dynamically regulates heterochromatin and repetitive element unsilencing in nucleus accumbens. Proc Natl Acad Sci USA. 2011;108:3035–40.

  90. 90.

    Flagel SB, Chaudhury S, Waselus M, Kelly R, Sewani S, Clinton SM, et al. Genetic background and epigenetic modifications in the core of the nucleus accumbens predict addiction-like behavior in a rat model. Proc Natl Acad Sci USA. 2016;113:E2861–2870.

  91. 91.

    Maze I, Covington HE 3rd, Dietz DM, LaPlant Q, Renthal W, Russo SJ, et al. Essential role of the histone methyltransferase G9a in cocaine-induced plasticity. Science. 2010;327:213–6.

  92. 92.

    Maze I, Chaudhury D, Dietz DM, Von Schimmelmann M, Kennedy PJ, Lobo MK, et al. G9a influences neuronal subtype specification in striatum. Nat Neurosci. 2014;17:533–9.

  93. 93.

    Aguilar-Valles A, Vaissiere T, Griggs EM, Mikaelsson MA, Takacs IF, Young EJ, et al. Methamphetamine-associated memory is regulated by a writer and an eraser of permissive histone methylation. Biol Psychiatry. 2014;76:57–65.

  94. 94.

    Damez-Werno DM, Sun H, Scobie KN, Shao N, Rabkin J, Dias C, et al. Histone arginine methylation in cocaine action in the nucleus accumbens. Proc Natl Acad Sci USA. 2016;113:9623–8.

  95. 95.

    Heller EA, Cates HM, Pena CJ, Sun H, Shao N, Feng J, et al. Locus-specific epigenetic remodeling controls addiction- and depression-related behaviors. Nat Neurosci. 2014;17:1720–7.

  96. 96.

    Renthal W, Nestler EJ. Epigenetic mechanisms in drug addiction. Trends Mol Med. 2008;14:341–50.

  97. 97.

    Hamilton PJ, Burek DJ, Lombroso SI, Neve RL, Robison AJ, Nestler EJ, et al. Cell-type-specific epigenetic editing at the fosb gene controls susceptibility to social defeat stress. Neuropsychopharmacology. 2018;43:272-84.

  98. 98.

    Bibb JA, Chen J, Taylor JR, Svenningsson P, Nishi A, Snyder GL, et al. Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5. Nature. 2001;410:376–80.

  99. 99.

    Heller EA, Hamilton PJ, Burek DD, Lombroso SI, Pena CJ, Neve RL, et al. Targeted epigenetic remodeling of the Cdk5 gene in nucleus accumbens regulates cocaine- and stress-evoked behavior. J Neurosci. 2016;36:4690–7.

  100. 100.

    Meyer DA, Richer E, Benkovic SA, Hayashi K, Kansy JW, Hale CF, et al. Striatal dysregulation of Cdk5 alters locomotor responses to cocaine, motor learning, and dendritic morphology. Proc Natl Acad Sci USA. 2008;105:18561–6.

  101. 101.

    Taylor JR, Lynch WJ, Sanchez H, Olausson P, Nestler EJ, Bibb JA. Inhibition of Cdk5 in the nucleus accumbens enhances the locomotor-activating and incentive-motivational effects of cocaine. Proc Natl Acad Sci USA. 2007;104:4147–52.

  102. 102.

    Vaillancourt K, Ernst C, Mash D, Turecki G. DNA methylation dynamics and cocaine in the brain: progress and prospects. Genes. 2017;8:E138.

  103. 103.

    Fasolino M, Zhou Z. The crucial role of DNA methylation and MeCP2 in neuronal function. Genes. 2017;8:E141.

  104. 104.

    Wright KN, Hollis F, Duclot F, Dossat AM, Strong CE, Francis TC, et al. Methyl supplementation attenuates cocaine-seeking behaviors and cocaine-induced c-Fos activation in a DNA methylation-dependent manner. J Neurosci. 2015;35:8948–58.

  105. 105.

    LaPlant Q, Vialou V, Covington HE 3rd, Dumitriu D, Feng J, Warren BL, et al. Dnmt3a regulates emotional behavior and spine plasticity in the nucleus accumbens. Nat Neurosci. 2010;13:1137–43.

  106. 106.

    Heiman M, Schaefer A, Gong S, Peterson JD, Day M, Ramsey KE, et al. A translational profiling approach for the molecular characterization of CNS cell types. Cell. 2008;135:738–48.

  107. 107.

    Grimm JW, Hope BT, Wise RA, Shaham Y. Neuroadaptation. Incubation of cocaine craving after withdrawal. Nature. 2001;412:141–2.

  108. 108.

    Massart R, Barnea R, Dikshtein Y, Suderman M, Meir O, Hallett M, et al. Role of DNA methylation in the nucleus accumbens in incubation of cocaine craving. J Neurosci. 2015;35:8042–58.

  109. 109.

    Deng JV, Rodriguiz RM, Hutchinson AN, Kim IH, Wetsel WC, West AE. MeCP2 in the nucleus accumbens contributes to neural and behavioral responses to psychostimulants. Nat Neurosci. 2010;13:1128–36.

  110. 110.

    Im HI, Hollander JA, Bali P, Kenny PJ. MeCP2 controls BDNF expression and cocaine intake through homeostatic interactions with microRNA-212. Nat Neurosci. 2010;13:1120–7.

  111. 111.

    Sato F, Tsuchiya S, Meltzer SJ, Shimizu K. MicroRNAs and epigenetics. FEBS J. 2011;278:1598–609.

  112. 112.

    Doura MB, Unterwald EM. MicroRNAs modulate interactions between stress and risk for cocaine addiction. Front Cell Neurosci. 2016;10:125.

  113. 113.

    Bastle RM, Oliver RJ, Gardiner AS, Pentkowski NS, Bolognani F, Allan AM, et al. In silico identification and in vivo validation of miR-495 as a novel regulator of motivation for cocaine that targets multiple addiction-related networks in the nucleus accumbens. Mol Psychiatry. 2018;23:434-43.

  114. 114.

    Feng J, Shao N, Szulwach KE, Vialou V, Huynh J, Zhong C, et al. Role of Tet1 and 5-hydroxymethylcytosine in cocaine action. Nat Neurosci. 2015;18:536–44.

  115. 115.

    Waddington CH. Canalization of development and genetic assimilation of acquired characters. Nature. 1959;183:1654–5.

  116. 116.

    Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. Genes Dev. 2009;23:781–3.

  117. 117.

    Pembrey ME, Bygren LO, Kaati G, Edvinsson S, Northstone K, Sjostrom M, et al. Sex-specific, male-line transgenerational responses in humans. Eur J Hum Genet. 2006;14:159–66.

  118. 118.

    Kaati G, Bygren LO, Edvinsson S. Cardiovascular and diabetes mortality determined by nutrition during parents’ and grandparents’ slow growth period. Eur J Hum Genet. 2002;10:682–8.

  119. 119.

    Puri D, Dhawan J, Mishra RK. The paternal hidden agenda: epigenetic inheritance through sperm chromatin. Epigenetics. 2010;5:386–91.

  120. 120.

    Hackett JA, Sengupta R, Zylicz JJ, Murakami K, Lee C, Down TA, et al. Germline DNA demethylation dynamics and imprint erasure through 5-hydroxymethylcytosine. Science. 2013;339:448–52.

  121. 121.

    Hammoud SS, Nix DA, Zhang H, Purwar J, Carrell DT, Cairns BR. Distinctive chromatin in human sperm packages genes for embryo development. Nature. 2009;460:473–8.

  122. 122.

    Vassoler FM, Byrnes EM, Pierce RC. The impact of exposure to addictive drugs on future generations: physiological and behavioral effects. Neuropharmacology. 2014a;76:269–75.

  123. 123.

    Vassoler FM, Sadri-Vakili G. Mechanisms of transgenerational inheritance of addictive-like behaviors. Neuroscience. 2014b;264C:198–206.

  124. 124.

    Yohn NL, Bartolomei MS, Blendy JA. Multigenerational and transgenerational inheritance of drug exposure: the effects of alcohol, opiates, cocaine, marijuana, and nicotine. Prog Biophys Mol Biol. 2015;118:21–33.

  125. 125.

    Abel EL, Moore C, Waselewsky D, Zajac C, Russell LD. Effects of cocaine hydrochloride on reproductive function and sexual behavior of male rats and on the behavior of their offspring. J Androl. 1989;10:17–27.

  126. 126.

    Vassoler FM, White SL, Schmidt HD, Sadri-Vakili G, Pierce RC. Epigenetic inheritance of a cocaine-resistance phenotype. Nat Neurosci. 2013b;16:42–47.

  127. 127.

    White SL, Vassoler FM, Schmidt HD, Pierce RC, Wimmer ME. Enhanced anxiety in the male offspring of sires that self-administered cocaine. Addict. Biol. 2016;21:802-10.

  128. 128.

    Wimmer ME, Briand LA, Fant B, Guercio LA, Arreola AC, Schmidt HD, et al. Paternal cocaine taking elicits epigenetic remodeling and memory deficits in male progeny. Mol Psychiatry. 2017;22:1641-50.

  129. 129.

    He F, Lidow IA, Lidow MS. Consequences of paternal cocaine exposure in mice. Neurotoxicol Teratol. 2006;28:198–209.

  130. 130.

    Killinger CE, Robinson S, Stanwood GD. Subtle biobehavioral effects produced by paternal cocaine exposure. Synapse. 2012;66:902–8.

  131. 131.

    Le Q, Yan B, Yu X, Li Y, Song H, Zhu H, et al. Drug-seeking motivation level in male rats determines offspring susceptibility or resistance to cocaine-seeking behaviour. Nat Commun. 2017;8:15527.

  132. 132.

    Fischer DK, Rice RC, Martinez Rivera A, Donohoe M, Rajadhyaksha AM. Altered reward sensitivity in female offspring of cocaine-exposed fathers. Behav Brain Res. 2017;332:23–31.

  133. 133.

    Becker JB, Hu M. Sex differences in drug abuse. Front Neuroendocrinol. 2008;29:36–47.

  134. 134.

    Chung WC, Swaab DF, De Vries GJ. Apoptosis during sexual differentiation of the bed nucleus of the stria terminalis in the rat brain. J Neurobiol. 2000;43:234–43.

  135. 135.

    Wee S, Hicks MJ, De BP, Rosenberg JB, Moreno AY, Kaminsky SM, et al. Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effects. Neuropsychopharmacology. 2011.

  136. 136.

    Kantak KM, Collins SL, Lipman EG, Bond J, Giovanoni K, Fox BS. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology. 2000;148:251–62.

  137. 137.

    Kinsey BM, Kosten TR, Orson FM. Anti-cocaine vaccine development. Expert Rev Vaccine. 2010;9:1109–14.

  138. 138.

    Zlebnik NE, Brimijoin S, Gao Y, Saykao AT, Parks RJ, Carroll ME. Long-term reduction of cocaine self-administration in rats treated with adenoviral vector-delivered cocaine hydrolase: evidence for enzymatic activity. Neuropsychopharmacology. 2014;39:1538–46.

  139. 139.

    Chen X, Xue L, Hou S, Jin Z, Zhang T, Zheng F, et al. Long-acting cocaine hydrolase for addiction therapy. Proc Natl Acad Sci USA. 2016;113:422–7.

  140. 140.

    Bolloni C, Panella R, Pedetti M, Frascella AG, Gambelunghe C, Piccoli T, et al. Bilateral transcranial magnetic stimulation of the prefrontal cortex reduces cocaine intake: a pilot study. Front Psychiatry. 2016;7:133.

  141. 141.

    Hanlon CA, Dowdle LT, Jones JL. Biomarkers for success: using neuroimaging to predict relapse and develop brain stimulation treatments for cocaine-dependent individuals. Int Rev Neurobiol. 2016;129:125–56.

  142. 142.

    Pierce RC, Vassoler FM. Deep brain stimulation for the treatment of addiction: basic and clinical studies and potential mechanisms of action. Psychopharmacology. 2013;229:487–91.

  143. 143.

    Vassoler FM, Schmidt HD, Gerard ME, Famous KR, Ciraulo DA, Kornetsky C, et al. Deep brain stimulation of the nucleus accumbens shell attenuates cocaine priming-induced reinstatement of drug seeking in rats. J Neurosci. 2008;28:8735–9.

  144. 144.

    Vassoler FM, White SL, Hopkins TJ, Guercio LA, Espallergues J, Berton O, et al. Deep brain stimulation of the nucleus accumbens shell attenuates cocaine reinstatement through local and antidromic activation. J Neurosci. 2013a;33:14446–54.

  145. 145.

    Creed M, Pascoli VJ, Luscher C. Addiction therapy. Refining deep brain stimulation to emulate optogenetic treatment of synaptic pathology. Science. 2015;347:659–64.

  146. 146.

    Guercio LA, Schmidt HD, Pierce RC. Deep brain stimulation of the nucleus accumbens shell attenuates cue-induced reinstatement of both cocaine and sucrose seeking in rats. Behav Brain Res. 2015;281:125–30.

  147. 147.

    Goncalves-Ferreira A, do Couto FS, Rainha Campos A, Lucas Neto LP, Goncalves-Ferreira D, Teixeira J. Deep brain stimulation for refractory cocaine dependence. Biol Psychiatry. 2016;79:e87–89.

  148. 148.

    Luigjes J, van den Brink W, Feenstra M, van den Munckhof P, Schuurman PR, Schippers R, et al. Deep brain stimulation in addiction: a review of potential brain targets. Mol Psychiatry. 2012;17:572–83.

  149. 149.

    Ghodke-Puranik Y, Thorn CF, Lamba JK, Leeder JS, Song W, Birnbaum AK, et al. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharm Genom. 2013;23:236–41.

  150. 150.

    Reid MS, Casadonte P, Baker S, Sanfilipo M, Braunstein D, Hitzemann R, et al. A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10/L-carnitine for the treatment of cocaine dependence. Addiction. 2005;100:43–57.

  151. 151.

    Halikas JA, Center BA, Pearson VL, Carlson GA, Crea F. A pilot, open clinical study of depakote in the treatment of cocaine abuse. Hum Psychopharmacol. 2001;16:257–64.

  152. 152.

    Reid MS, Thakkar V. Valproate treatment and cocaine cue reactivity in cocaine dependent individuals. Drug Alcohol Depend. 2009;102:144–50.

Download references

Author information


  1. Department of Psychiatry, Center for Neurobiology and Behavior, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA

    • R. Christopher Pierce
    • , Bruno Fant
    • , Sarah E. Swinford-Jackson
    •  & Wade H. Berrettini
  2. Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA

    • Elizabeth A. Heller
  3. Department of Psychology, Temple University, Philadelphia, PA, 19122, USA

    • Mathieu E. Wimmer


  1. Search for R. Christopher Pierce in:

  2. Search for Bruno Fant in:

  3. Search for Sarah E. Swinford-Jackson in:

  4. Search for Elizabeth A. Heller in:

  5. Search for Wade H. Berrettini in:

  6. Search for Mathieu E. Wimmer in:

Conflict of interest

The authors declare that they have no conflict of interest.

Corresponding author

Correspondence to R. Christopher Pierce.

About this article

Publication history